Related references
Note: Only part of the references are listed.A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
E. Angevin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Eric Angevin et al.
CLINICAL CANCER RESEARCH (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma
Jennifer R. Diamond et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
AMG 386 in Combination With Sorafenib in Patients With Metastatic Clear Cell Carcinoma of the Kidney A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
Brian Rini et al.
CANCER (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma
Dale R. Shepard et al.
INVESTIGATIONAL NEW DRUGS (2012)
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Dmitry A. Nosov et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases
Junichi Shindoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm
Sumanta Kumar Pal et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen et al.
LANCET ONCOLOGY (2012)
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2011)
Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1,-2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A. L. M. Eskens et al.
CLINICAL CANCER RESEARCH (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Farbod Shojaei et al.
CANCER RESEARCH (2010)
The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (Publication with Expression of Concern. See vol. 25, pg. 4194, 2019)
Daniel C. Cho et al.
CLINICAL CANCER RESEARCH (2010)
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.
I. Brana et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Role of Fibroblast Growth Factors in Tumor Growth
M. Korc et al.
CURRENT CANCER DRUG TARGETS (2009)
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model
Eri Taguchi et al.
CANCER SCIENCE (2008)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC)
T. K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Renal cell carcinoma guideline
Borje Ljungberg et al.
EUROPEAN UROLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties
Kazuhide Nakamura et al.
CANCER RESEARCH (2006)
CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia
DEL de Menezes et al.
CLINICAL CANCER RESEARCH (2005)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia
MJ Currie et al.
JOURNAL OF PATHOLOGY (2002)
Share Paper
